Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer

Xu, Jianming; Jiang, Haiping; Pan, Yueyin; Gu, Kangsheng; Cang, Shundong; Han, Lei; Shu, Yongqian; Li, Jiayi; Zhao, Junhui; Pan, Hongming; Luo, Suxia; Qin, Yanru; Guo, Qunyi; Bai, Yuxian; Yang, Ling; Yang, Jianwei; Yan, Zhilong; Yang, Lei; Tang, Yong; He, Yifu; Zhang, Liangming; Liang, Xinjun; Niu, Zuoxing; Zhang, Jingdong; Mao, Yong; Guo, Yingmei; Peng, Bo; Li, Ziran; Liu, Ying; Wang, Yan; Zhou, Hui; Investigators, ORIENT-16; Sun, Hongmei; Wang, Qi; Li, Junhe; Jiang, Da; Guo, Weijian; Ying, Jieer; Wang, Shubin; Zang, Aimin; Cai, Shirong; Hu, Chunhong; Zhang, Tao; Tao, Min; Liang, Jun; Mao, Qinsheng; Zhang, Minghui; Mao, Rui; Yang, Hui; Zhang, Hongyu; Shen, Lin; Lu, Jin; Li, Wenxin; Chen, Yamin; Chen, Lei; Zhuang, Zhixiang; Bai, Chunmei; Liu, Heli; Chen, Jingtang; Liao, Wangjun; Qiu, Meng; Song, Rongfeng; Li, Man; B. Qian, S.; Liu, Yunpeng; Liu, Jiang; Wang, Dong; Yin, Xianli; Huang, Zhiming

doi:10.1001/jama.2023.19918

Public

Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer

Published in JAMA • Dec 5, 2023

Authors:

Jianming Xu

Haiping Jiang

Yueyin Pan

Abstract

Importance: Gastric and gastroesophageal junction cancers are diagnosed in more than 1 million people worldwide annually, and few effective treatments are available. Sintilimab, a recombinant human IgG4 monoclonal antibody that binds to programmed cell death 1 (PD-1), in combination with chemotherap...

Subject

Medicine

Internal medicine

Capecitabine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!